Read by QxMD icon Read


Deanna J Taylor, Nicholas D Smith, Alison M Binns, David P Crabb
PURPOSE: There is a well-established research base surrounding face recognition in patients with age-related macular degeneration (AMD). However, much of this existing research does not differentiate between results obtained for 'wet' AMD and 'dry' AMD. Here, we test the hypothesis that face recognition performance is worse in patients with dry AMD compared with visually healthy peers. METHODS: Patients (>60 years of age, logMAR binocular visual acuity 0.7 or better) with dry AMD of varying severity and visually healthy age-related peers (controls) completed a modified version of the Cambridge Face Memory Test (CFMT)...
February 27, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
Luis Hernandez, Tereza Lanitis, Clifford Cele, Hector Toro-Diaz, Andrea Gibson, Andreas Kuznik
BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of vision loss in the United States. The most severe vision loss occurs in patients with neovascular AMD, known as wet AMD (wAMD). The most commonly used antivascular endothelial growth factor (VEGF) therapies approved by the FDA to treat patients with wAMD are ranibizumab, 0.5 mg administered by intravitreal injection once a month (approximately every 28 days), and intravitreal aflibercept injection (IAI), 2 mg every 4 weeks (monthly) for the first 12 weeks (3 months), followed by IAI 2 mg once every 8 weeks (2 months)...
February 16, 2018: Journal of Managed Care & Specialty Pharmacy
Shang Chen, Yue Zhou, Lichun Zhou, Yanhui Guan, Yu Zhang, Xiuzhen Han
Choroidal neovascularization (CNV) is the hallmark of late-staged wet age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is a key component in the development and progression of wet AMD. DMBT, 6,6'-bis(2,3-dimethoxybenzoyl)-α,α-D-trehalose, had been proved that it could suppress tumor angiogenesis and metastasis by inhibiting production of VEGF. But the effects of DMBT on CNV were not known. This study was to investigate effects and mechanisms of DMBT on CNV in vitro and in vivo...
February 14, 2018: Molecular and Cellular Biochemistry
Katja Hatz, Frank Zimmermann, Dimitrios Kardamakis, Emmanouil Lazaridis, Cengiz Türksever, Jörg Binder, Alexandros Papachristofilou, Christian Prünte
BACKGROUND AND OBJECTIVE: To evaluate the effectiveness and safety of low-energy stereotactic radiotherapy (SRT) combined with anti-vascular endothelial growth factor (VEGF) treatment following a treat-and-extend regimen (TER) in wet age-related macular degeneration (AMD). PATIENTS AND METHODS: Before/after SRT, the authors compared retrospective consecutive case series of 50 patients requiring frequent anti-VEGF treatment (every 4 or 6 weeks) in wet AMD, treated with a single session of SRT and TER (same manner pre/post-SRT)...
February 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
Xavier Corveleyn, Quentin Lenoble, Sébastien Szaffarczyk, Thi Ha Chau Tran, Muriel Boucart
SIGNIFICANCE: Vision is paramount for motor actions directed toward objects. Vision allows not only the identification of objects and their shape and spatial location, but also the adaptation of our movement when it arrives on the object. These findings show that vision deficits, as in age-related macular degeneration (AMD), can lead to reaching and grasping deficits. PURPOSE: Few studies have investigated reaching and grasping in patients with AMD. They showed a deficit in the execution of motor actions in people with AMD, even though these people do not mention difficulties in their daily lives...
February 8, 2018: Optometry and Vision Science: Official Publication of the American Academy of Optometry
Justus G Garweg, Johanna J Zirpel, Christin Gerhardt, Isabel B Pfister
PURPOSE: Real-life studies on long-term functional outcome of anti-VEGF treatment for wet age-related macular degeneration (wAMD) are limited. We therefore assessed the 10-year outcomes in our patients. METHODS: In this retrospective study, all patients with newly diagnosed wAMD that had received minimally three intravitreal injections between 2007 and 2012 and a follow-up of ≥48 months were included. Primary outcome measure was the evolution of best-corrected visual acuity (BCVA) over time...
February 3, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
Deborah Cohen
No abstract text is available yet for this article.
January 24, 2018: BMJ: British Medical Journal
Tim J Enz, Livia Faes, Lucas M Bachmann, Michael A Thiel, Jeremy P Howell, Sophie C Boehni, Mario Bittner, Martin K Schmid
PURPOSE: To evaluate differences in postoperative central macular thickness, central macular volume, corrected distance visual acuity (CDVA), and number of intravitreal anti-vascular endothelial growth factor (VEGF) injections between conventional and femtosecond laser-assisted cataract surgery in wet age-related macular degeneration (AMD). SETTING: Tertiary referral center, Lucerne, Switzerland. DESIGN: Retrospective case series. METHODS: Consecutive patients with AMD and cataract were enrolled between January 2010 and December 2015...
January 17, 2018: Journal of Cataract and Refractive Surgery
Francine Behar-Cohen
AMD is the major cause of visual loss in individuals older than 50 in the western countries. Whilst tremendous progress has been made by the intraocular repeated injections of anti-VEGFs in wet AMD, no treatment is recognized to prevent progression of dry AMD, which represents more than 50 % of the cases. Interestingly, an over activation of the complement alternative pathway has been associated to both forms of AMD. But, several clinical studies have failed to demonstrate any efficacy of molecules blocking the complement pathway at various stage of its activation...
January 10, 2018: Revue Médicale Suisse
Wen Yang, Ying Tan, Chaowei Li, Yi Liu, Guohua Lu
To observe the clinical efficacy of intravitreal injection of conbercept in the treatment of wet age-related macular degeneration (wAMD), optical coherence tomography (OCT) and the best corrected visual acuity (BCVA) was observed to measure the changes of anatomical changes of central macular thickness (CMT) and the area and volume of retinal pigment epithelium (RPE) uplift. Fifteen patients (15 eyes) with wet AMD were enrolled in this study. All patients underwent intravitreal injection of conbercept of 0...
January 10, 2018: Microscopy Research and Technique
Mehmet Ozgur Zengin, Omer Karti, Eyyup Karahan, Tuncay Kusbeci
BACKGROUND AND OBJECTIVE: To evaluate the relationship between age-related macular degeneration (AMD) and clinically unilateral pseudoexfoliation syndrome (XFS). PATIENTS AND METHODS: Seventy-six patients (152 eyes) with bilateral AMD and clinically unilateral XFS were included. Eyes with AMD were divided into three stages (early, intermediate, and late), based on the Beckman Initiative for Macular Research Classification Committee of fundus findings. The distribution of AMD lesions was assessed in both groups, and the subfoveal choroidal thickness (SFCT) was measured using enhanced depth imaging spectral-domain optical coherence tomography (SD-OCT)...
January 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
Yumiko Akagi-Kurashige, Akitaka Tsujikawa, Mitsuko Yuzawa, Tatsuro Ishibashi, Hideo Nakanishi, Eiji Nakatani, Satoshi Teramukai, Masanori Fukushima, Nagahisa Yoshimura
PURPOSE: In this study (AMD2000), we aimed to determine the visual prognosis of Japanese patients with age-related macular degeneration (AMD). METHODS: This was a multicenter prospective observational cohort study. In total, 460 patients with AMD were recruited from April 2006 to March 2009 from 18 clinical trial sites in Japan. They were followed up for 5 years, as they continued to receive medical treatment. RESULTS: Of the 409 study eyes followed up for at least 1 year, 243 eyes (59...
March 2018: Japanese Journal of Ophthalmology
Rania S Sulaiman, Bomina Park, Sardar Pasha Sheik Pran Babu, Yubing Si, Rakshin Kharwadkar, Sayak K Mitter, Bit Lee, Wei Sun, Xiaoping Qi, Michael E Boulton, Samy O Meroueh, Xiang Fei, Seung-Yong Seo, Timothy W Corson
The standard-of-care therapeutics for the treatment of ocular neovascular diseases like wet age-related macular degeneration (AMD) are biologics targeting vascular endothelial growth factor signaling. There are currently no FDA approved small molecules for treating these blinding eye diseases. Therefore, therapeutic agents with novel mechanisms are critical to complement or combine with existing approaches. Here, we identified soluble epoxide hydrolase (sEH), a key enzyme for epoxy fatty acid metabolism, as a target of an antiangiogenic homoisoflavonoid, SH-11037...
January 19, 2018: ACS Chemical Biology
Dimitrios Karagiannis, Irini Chatziralli, Konstantinos Kaprinis, Ilias Georgalas, Efstratios Parikakis, Panagiotis Mitropoulos
Purpose: To evaluate the anatomical and functional outcomes in patients with submacular hemorrhage (SMH) due to age-related macular degeneration (AMD) treated with ranibizumab, and to evaluate the potential role of the SMH location in the final outcome after treatment. Methods: Participants in this study were 12 treatment-naïve patients with SMH due to neovascular AMD who were treated with intravitreal ranibizumab and had at least 12 months' follow-up. All patients underwent best-corrected visual acuity measurement and optical coherence tomography at baseline and at every visit posttreatment, while fluorescein angiography was done at baseline and at the discretion of the physician thereafter...
2017: Clinical Interventions in Aging
Norshakimah Md Bakri, Vasudevan Ramachandran, Hoo Fan Kee, Visvaraja Subrayan, Hazlita Isa, Nor Fariza Ngah, Nur Afiqah Mohamad, Ching Siew Mooi, Chan Yoke Mun, Patimah Ismail, Fazliana Ismail, Erma Suryana Sukiman, Wan Alia Wan Sulaiman
Age-related macular degeneration (AMD) is the most widely recognised cause of irreversible vision loss and previous studies have suggested that the advancement of wet AMD is influenced by both modifiable and non-modifiable elements. Single nucleotide polymorphism (SNPs) and copy number of variations (CNVs) have been associated with AMD in various populations, however the results are conflicting. Our aim is to determine the CNVs of Complement Factor H-Related genes among Malaysian subjects with wet AMD. 130 patients with wet AMD and 120 healthy controls were included in this research...
December 2017: Kaohsiung Journal of Medical Sciences
Mohammed Ashraf, Ahmed Souka, Ron A Adelman
To assess predictors of treatment response in neovascular age-related macular degeneration (AMD) in an attempt to develop a patient-centric treatment algorithm. We conducted a systematic search using PubMed, EMBASE and Web of Science for prognostic indicators/predictive factors with the key words: 'age related macular degeneration', 'neovascular AMD', 'choroidal neovascular membrane (CNV)', 'anti-vascular endothelial growth factor (anti-VEGF)', 'aflibercept', 'ranibizumab', 'bevacizumab', 'randomized clinical trials', 'post-hoc', 'prognostic', 'predictive', 'response' 'injection frequency, 'treat and extend (TAE), 'pro re nata (PRN)', 'bi-monthly' and 'quarterly'...
November 11, 2017: Acta Ophthalmologica
Irini Chatziralli, Panagiotis Stavrakas, George Theodossiadis, Konstantinos Ananikas, Eleni Dimitriou, Panagiotis Theodossiadis
PURPOSE: The purpose of this prospective study was to evaluate the impact of epiretinal membrane (ERM) on anatomical and functional results in patients with wet age-related macular degeneration (AMD) treated with intravitreal anti-vascular endothelial growth (anti-VEGF) injections. METHODS: Participants in the study were 48 patients with either wet AMD alone (AMD group, n = 27) or AMD and ERM (AMD/ERM group, n = 21). All patients received intravitreal anti-VEGF injections (three monthly injections and PRN thereafter) and were followed up for at least 12 months...
November 8, 2017: Seminars in Ophthalmology
Deborah Cohen
No abstract text is available yet for this article.
October 31, 2017: BMJ: British Medical Journal
P Kunumpol, W Umpaipant, N Kanchanaranya, T Charoenpong, S Vongkittirux, T Kupakanjana, C Tantibundhit
This work proposed an automated screening system for Age-related Macular Degeneration (AMD), and distinguishing between wet or dry types of AMD using fundus images to assist ophthalmologists in eye disease screening and management. The algorithm employs contrast-limited adaptive histogram equalization (CLAHE) in image enhancement. Subsequently, discrete wavelet transform (DWT) and locality sensitivity discrimination analysis (LSDA) were used to extract features for a neural network model to classify the results...
July 2017: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
J Zerbib, A Bourhis, P L Cornut, F De Bats, V Gualino, J Halfon, H Massé, M Srour, M Streho, S Tick, B Wolff, N San Nicolas
PURPOSE AND CONTEXT: Intravitreal administration of anti-VEGF agents, available in France since 2007, allows stabilization and improvement in visual acuity in wet age-related macular degeneration (AMD). In the past few years, the management of this disease has evolved in terms of both diagnostic methods and treatment schedules, which have been adapted to the pathophysiology of AMD. The goal of this survey, performed in a representative sample of French ophthalmologists, was to describe the evolution of medical practices one year after a similar survey (Massé et al...
November 2017: Journal Français D'ophtalmologie
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"